Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Mirococept (APT070), an antibody designed to target the complement system components C3b/C4b and act as a membrane-localizing C3 convertase inhibitor, effectively diminishes the release of C-peptide and pro-inflammatory cytokines. It also curtails the infiltration of inflammatory cells and intraislet inflammation, offering advantages for islet transplantation. Furthermore, Mirococept mitigates increased vascular permeability in intestinal and pulmonary contexts, thereby reducing neutrophil influx [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Mirococept (APT070), an antibody designed to target the complement system components C3b/C4b and act as a membrane-localizing C3 convertase inhibitor, effectively diminishes the release of C-peptide and pro-inflammatory cytokines. It also curtails the infiltration of inflammatory cells and intraislet inflammation, offering advantages for islet transplantation. Furthermore, Mirococept mitigates increased vascular permeability in intestinal and pulmonary contexts, thereby reducing neutrophil influx [1] [2]. |
Molecular Weight | N/A |
CAS No. | 507453-82-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Mirococept 507453-82-9 inhibitor inhibit